Dr. Martens (LON:DOCS) Upgraded to Buy at Peel Hunt

Dr. Martens (LON:DOCS) was upgraded by Peel Hunt to a “buy” rating in a report issued on Monday, Marketbeat Ratings reports.

Several other research analysts also recently issued reports on DOCS. Royal Bank Of Canada dropped their price objective on shares of Dr. Martens from GBX 7,000 ($94.56) to GBX 6,000 ($81.05) and set a “sector perform” rating on the stock in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Dr. Martens in a research report on Friday, July 11th.

Dr. Martens Stock Performance

DOCS opened at GBX 84 ($1.13) on Monday. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The stock’s 50 day moving average price is GBX 77.48 and its two-hundred day moving average price is GBX 65.30. The firm has a market capitalization of £815.44 million, a P/E ratio of 11.91, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. Dr. Martens has a 12-month low of GBX 43.02 ($0.58) and a 12-month high of GBX 85.41 ($1.15).

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 ($0.03) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities analysts forecast that Dr. Martens will post 2.5809394 earnings per share for the current year.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.